RxDoctor Payments DataLook up a doctor →

David Wright, MD

Medical Oncology · Tampa, FLNPI 1699745638

Payments from drug & device makers

$3,349,583in general payments, 2019–2025

Across 1,459 payments — averaging $2295.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$1.4M
  • AstraZeneca$542K
  • Bristol Myers Squibb$401K
  • Pharmacyclics LLC, An Abbvie Company$289K
  • E.r. Squibb & Sons, L.L.C.$206K
  • Sanofi US Services Inc.$159K
  • plus $323K from 54 others
$1,447in research payments, 2019–2025

Across 2 payments — averaging $723.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$1K

What the payments were for

  • Consulting fees$14,68931%
  • Speaking & faculty fees$10,66322%
  • Travel & lodging$120%
  • Food & beverage$22,00546%
  • Education$1170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astrazeneca UK Limited16$1,429,574
AstraZeneca(2 entities)56$541,505
Bristol Myers Squibb73$401,360
Pharmacyclics LLC, An Abbvie Company135$288,999
E.r. Squibb & Sons, L.L.C.109$206,323
Sanofi US Services Inc.26$158,700
Genentech, Inc.36$110,175
Merck75$82,254
Verastem, Inc.40$57,355
AbbVie34$28,701
Myriad Genetic Laboratories, Inc.4$8,052
TG Therapeutics, Inc.5$7,797
Gilead(2 entities)58$6,678
Pfizer76$6,183
Novartis121$1,909
Johnson & Johnson67$1,428
Epizyme, Inc.2$1,268
Lilly USA, LLC40$889
Incyte Corporation34$793
Eisai Inc.32$691
Sanofi30$649
Amgen23$528
Tersera Therapeutics LLC17$515
Genentech USA, Inc.35$492
Exelixis Inc.28$485
Seagen Inc.23$458
Regeneron Healthcare Solutions, Inc.16$438
Daiichi Sankyo Inc.17$435
GSK16$368
Bayer15$292
Astellas Pharma US Inc14$260
Puma Biotechnology, Inc.12$215
Rigel Pharmaceuticals, Inc.4$204
Deciphera Pharmaceuticals Inc.11$200
Beigene USA, Inc.8$194
Takeda Pharmaceuticals U.S.A., Inc.8$191
Athenex Pharmaceutical Division, LLC1$175
Mirati Therapeutics, Inc.7$154
Blueprint Medicines Corporation7$153
Dendreon Pharmaceuticals LLC5$152
Karyopharm Therapeutics Inc.8$144
AVEO Pharmaceuticals, Inc.7$137
Sumitomo Pharma America, Inc.8$136
Pharmaessentia USA Corporation6$135
Jazz Pharmaceuticals Inc.6$120
Ipsen Biopharmaceuticals, Inc7$119
Tetraphase Pharmaceuticals, Inc.2$106
Tempus AI, Inc4$95
Array Biopharma Inc6$90
Taiho Oncology, Inc.5$86
Geron Corporation4$84
Legend Biotech USA Inc.3$83
Stemline Therapeutics Inc.4$82
EMD Serono, Inc.4$81
Sobi, Inc3$80
Genmab U.S., Inc.3$67
Springworks Therapeutics, Inc.2$55
Aadi Bioscience, Inc.1$47
CTI Biopharma Corp.3$45
Clovis Oncology, Inc.3$39

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,349,583 in reported general payments places this provider in the 90th percentile of 507 medical oncology providers in Florida.

See all medical oncology providers in Florida

Medicare billing

Part B allowed, 2024
$5,934,022
Medicare patients
1,266
Services billed
280,435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide138$2,033,507
JakafiRuxolitinib Phosphate36$616,414
PomalystPomalidomide27$603,874
ImbruvicaIbrutinib33$518,294
IbrancePalbociclib33$511,757
BrukinsaZanubrutinib31$435,345
CalquenceAcalabrutinib Maleate32$392,777
PromactaEltrombopag Olamine18$310,832
XtandiEnzalutamide15$176,094
KisqaliRibociclib Succinate12$163,460
AlecensaAlectinib Hcl12$129,173
VenclextaVenetoclax19$107,903
EliquisApixaban105$74,314
XareltoRivaroxaban44$35,053
Abiraterone Acetate17$21,771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$401,360$2,033,507138 claims
Incyte CorporationJakafi$793$616,41436 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$206,323$603,87427 claims
PfizerIbrance, Eliquis$6,183$586,071138 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$288,999$518,29433 claims
NovartisPromacta, Kisqali$1,909$474,29230 claims
Beigene USA, Inc.Brukinsa$194$435,34531 claims
AstraZenecaCalquence$541,505$392,77732 claims
Astellas Pharma US IncXtandi$260$176,09415 claims
Genentech USA, Inc.Alecensa$492$129,17312 claims
AbbVieVenclexta$28,701$107,90319 claims
Johnson & JohnsonXarelto, Procrit$1,428$55,60857 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 507 medical oncology providers in Florida.

Other medical oncology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →